AZoLifeSciences on MSN
Genomic test can accurately identify early recurrence risk in prostate cancer patients
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
Live Science on MSN
New tests could nearly halve the rate of late-stage cancers, some scientists say — is that true?
The study suggests the tests could save lives by catching cancer at earlier stages, when it's more easily treated. It predicted that, over a decade of use, MCEDs could reduce stage IV cancer diagnoses ...
The MCED test shows similar performance in cancer survivors and the general population, with a PPV of 50% and high ...
TrinScreen HIV order signals renewed strength in global HIV testing market- Company also reports a key milestone of Adjusted EBITDA1positive ...
ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback